Literature DB >> 21680293

Oxaliplatin, colorectal cancer and predictive factors.

Albert Abad Esteve.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21680293     DOI： 10.1007/s12094-011-0666-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  9 in total

1.  A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.

Authors:  D J Park; J Stoehlmacher; W Zhang; D D Tsao-Wei; S Groshen; H J Lenz
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

2.  ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.

Authors:  Y Shirota; J Stoehlmacher; J Brabender; Y P Xiong; H Uetake; K D Danenberg; S Groshen; D D Tsao-Wei; P V Danenberg; H J Lenz
Journal:  J Clin Oncol       Date:  2001-12-01       Impact factor: 44.544

3.  Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients.

Authors:  Toshiaki Watanabe; Takashi Kobunai; Yoko Yamamoto; Keiji Matsuda; Soichiro Ishihara; Keijiro Nozawa; Hisae Iinuma; Tsuyoshi Konishi; Hisanaga Horie; Hiroki Ikeuchi; Kiyoshi Eshima; Tetsuichiro Muto
Journal:  Clin Transl Oncol       Date:  2011-06       Impact factor: 3.405

4.  Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.

Authors:  H-C Kwon; M S Roh; S Y Oh; S-H Kim; M C Kim; J-S Kim; H-J Kim
Journal:  Ann Oncol       Date:  2007-03       Impact factor: 32.976

5.  ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.

Authors:  David J Park; Wu Zhang; Jan Stoehlmacher; Denice Tsao-Wei; Susan Groshen; Ji Gil; Jim Yun; Erin Sones; Nalin Mallik; Heinz-Josef Lenz
Journal:  Clin Adv Hematol Oncol       Date:  2003-03

6.  Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer.

Authors:  Eva Martinez-Balibrea; Albert Abad; Enrique Aranda; Javier Sastre; Jose Luis Manzano; Eduardo Díaz-Rubio; Auxiliadora Gómez-España; Jorge Aparicio; Teresa García; Inmaculada Maestu; Anna Martínez-Cardús; Alba Ginés; Elisabet Guino
Journal:  Eur J Cancer       Date:  2008-04-28       Impact factor: 9.162

7.  Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer.

Authors:  Anna Martinez-Cardús; Eva Martinez-Balibrea; Eva Bandrés; Raquel Malumbres; Alba Ginés; José Luís Manzano; Miquel Taron; Jesús Garcia-Foncillas; Albert Abad
Journal:  Mol Cancer Ther       Date:  2009-01       Impact factor: 6.261

8.  Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.

Authors:  Sung-Hyun Kim; Hyuk-Chan Kwon; Sung Yong Oh; Dong Mee Lee; Suee Lee; Jong-Hoon Lee; Mee-Sook Roh; Dae-Cheol Kim; Ki-Jae Park; Hong-Jo Choi; Hyo-Jin Kim
Journal:  Am J Clin Oncol       Date:  2009-02       Impact factor: 2.339

9.  A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.

Authors:  J Stoehlmacher; D J Park; W Zhang; D Yang; S Groshen; S Zahedy; H-J Lenz
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.